博雅生物(300294) - 2024 Q3 - 季度财报

Financial Performance - Q3 2024 revenue was CNY 349,372,113.05, a decrease of 46.21% year-over-year, while total revenue for the first nine months was CNY 1,245,107,779.60, down 43.16% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was CNY 96,733,318.26, a decline of 29.98% year-over-year, with a nine-month total of CNY 412,703,629.27, down 11.07%[2]. - Operating revenue for the first nine months of 2024 was approximately ¥1.25 billion, a decrease of 43.16% compared to ¥2.19 billion in the same period of 2023[7]. - Total operating revenue for Q3 2024 was CNY 1,245,107,779.60, a decrease of 43.2% compared to CNY 2,190,398,869.51 in the same period last year[20]. - The net profit for Q3 2024 was CNY 412.43 million, a decrease of 13.00% compared to CNY 474.09 million in Q3 2023[21]. - The total profit for Q3 2024 was CNY 480.43 million, compared to CNY 575.20 million in Q3 2023, a decline of 16.49%[21]. Revenue and Costs - Total operating costs for Q3 2024 were CNY 853,438,255.57, down 51.2% from CNY 1,749,069,896.51 year-over-year[20]. - Operating costs for the same period were approximately ¥415 million, down 62.07% from ¥1.09 billion year-on-year[7]. - Cash received from sales of goods and services was approximately ¥1.19 billion, a decline of 47.40% compared to ¥2.25 billion in 2023[7]. - Cash paid for purchasing goods and services was approximately ¥334 million, down 63.82% from ¥923 million year-on-year[7]. - Sales expenses decreased by 39.71% to approximately ¥274 million from ¥454 million in the previous year[7]. - The company reported a significant reduction in sales expenses, which decreased to CNY 273,785,234.14 from CNY 454,124,674.39, a decline of 39.6%[20]. Assets and Equity - Total assets as of September 30, 2024, were CNY 8,157,947,458.71, reflecting a 4.20% increase from the end of the previous year[2]. - Shareholders' equity increased to CNY 7,581,179,585.65, up 3.57% from the end of the previous year[2]. - The company's total equity attributable to shareholders increased to CNY 7,581,179,585.65, compared to CNY 7,319,750,577.78, marking a growth of 3.6%[19]. - The company’s total current assets increased to RMB 6.59 billion from RMB 6.43 billion at the beginning of the period, reflecting a growth of approximately 2.5%[17]. - The company’s inventory rose to RMB 627.58 million, up from RMB 556.94 million, indicating an increase of about 12.7%[17]. - The company’s cash and cash equivalents at the end of the period were RMB 1.99 billion, compared to RMB 1.96 billion at the beginning, showing a slight increase of 1.4%[17]. Cash Flow - Cash flow from operating activities for the first nine months was CNY 262,408,653.79, a significant decrease of 50.08% compared to the same period last year[2]. - Cash flow from operating activities decreased to CNY 262.41 million in Q3 2024, compared to CNY 525.71 million in Q3 2023, a drop of 50.16%[23]. - The company reported a net cash inflow of approximately ¥109 million from the disposal of subsidiaries, a significant increase of 200.18% compared to ¥36 million in the previous year[7]. - The company recorded a net cash outflow from investment activities of CNY 53.56 million in Q3 2024, an improvement from a net outflow of CNY 519.77 million in Q3 2023[23]. - Cash flow from financing activities showed a net outflow of CNY 170.21 million in Q3 2024, compared to a net outflow of CNY 193.63 million in the same period last year, indicating a reduction of 12.56%[24]. Investments and Acquisitions - The company plans to increase investment in smart factory projects, with cash payments for fixed assets rising by 59.99% to approximately ¥119 million[7]. - The company has made a cash payment of ¥182 million related to the acquisition of Green Cross, indicating ongoing market expansion strategies[7]. - The company completed the acquisition of 100% equity in Green Cross Hong Kong Holdings Limited for RMB 1.82 billion, indirectly acquiring Green Cross (China) Biological Products Co., Ltd.[11]. Plasma Collection and Production - The blood products business generated revenue of CNY 1,089,481,025.84 for the first nine months, an increase of 0.39% year-over-year, driven by higher sales of prothrombin complex and factor VIII[3]. - The company collected 387.44 tons of raw plasma in the first nine months, representing a 12.39% increase compared to the previous year, due to improved local donation environments and service quality[3]. - The company’s subsidiary, Taihe Plasma Station, and Leping Plasma Station received the Single Plasma Collection License, enhancing the raw plasma supply capacity.[12]. - The company is actively advancing the construction of its intelligent blood product factory, with major structural work completed, marking a new phase in the project.[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,602, indicating a stable shareholder base[8]. - The company’s cash dividend distribution for the first half of 2024 is set at RMB 1.60 per 10 shares, totaling RMB 80.68 million, which accounts for 25.53% of the net profit attributable to shareholders for the same period.[14]. Research and Development - Research and development expenses for Q3 2024 amounted to CNY 47,378,915.31, slightly down from CNY 48,042,073.01 in the previous year[20].